Jupiter Neurosciences, Inc. (JUNS)
2.20
+0.07
(+3.29%)
USD |
NASDAQ |
Nov 06, 16:00
2.01
-0.19
(-8.64%)
After-Hours: 20:00
Jupiter Neurosciences Debt to Equity Ratio : -4.852 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.852 |
| March 31, 2026 | -1.745 |
| December 31, 2025 | -2.904 |
| September 30, 2025 | 3.303 |
| June 30, 2025 | 0.1442 |
| March 31, 2025 | 0.0671 |
| December 31, 2024 | 0.0522 |
| September 30, 2024 | -0.4221 |
| June 30, 2024 | -0.4498 |
| March 31, 2024 | -0.3798 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.3876 |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -0.2657 |
| September 30, 2022 | -0.2474 |
| June 30, 2022 | -0.202 |
| March 31, 2022 | -0.1232 |
| December 31, 2021 | -0.1258 |
| September 30, 2021 | -0.1511 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Johnson & Johnson | 0.5477 |
| ANI Pharmaceuticals, Inc. | 0.9531 |
| Corcept Therapeutics, Inc. | 0.0108 |
| Veru, Inc. | 0.0945 |
| Eli Lilly & Co. | 1.229 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.719M |
| Total Liabilities (Quarterly) | 4.085M |
| Shareholders Equity (Quarterly) | -0.366M |
| Current Ratio | 0.657 |
| Net Debt Paydown Yield | -2.94% |